Drug Price Trends for NDC 51672-2010

Average Pharmacy Cost for 51672-2010

Drug Name	NDC	Price/Unit ($)	Unit	Date
HYDROCORTISONE 0.5% CREAM	51672-2010-02	0.10880	GM	2026-03-18
HYDROCORTISONE 0.5% CREAM	51672-2010-02	0.11099	GM	2026-02-18
HYDROCORTISONE 0.5% CREAM	51672-2010-02	0.10842	GM	2026-01-21
HYDROCORTISONE 0.5% CREAM	51672-2010-02	0.10586	GM	2025-12-17

Best Wholesale Price for NDC 51672-2010

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC: 51672-2010

Last updated: February 18, 2026

Executive Summary

NDC 51672-2010, identified as Amlodipine Besylate 5mg Tablets, is a widely prescribed medication within the cardiovascular therapeutic class, primarily indicated for hypertension and angina pectoris. The market for Amlodipine Besylate is characterized by significant generic competition, driving down prices and focusing competition on manufacturing efficiency and market access. This analysis projects moderate price stability for the immediate future, with potential for slight erosion due to continued generic pressures and evolving reimbursement policies.

Market Overview

Amlodipine Besylate is a calcium channel blocker used to treat high blood pressure and chest pain (angina). Its established efficacy, favorable safety profile, and long history of use have cemented its position as a first-line treatment for these conditions.

Therapeutic Indications and Patient Population

• Hypertension: Amlodipine Besylate is a cornerstone therapy for the management of essential hypertension. The global prevalence of hypertension remains high, creating a consistent and substantial patient base.
• Angina Pectoris: It is also indicated for chronic stable angina and vasospastic angina (Prinzmetal's angina). While less prevalent than hypertension, angina still represents a significant market segment.

Competitive Landscape

The market for Amlodipine Besylate is highly fragmented due to patent expirations and the widespread availability of generic versions. Key market participants are primarily generic pharmaceutical manufacturers.

• Major Generic Manufacturers: Companies such as Teva Pharmaceuticals, Mylan (now Viatris), Sandoz (part of Novartis), and numerous other national and regional players produce and distribute generic Amlodipine Besylate.
• Branded vs. Generic: While a branded version (Norvasc, Pfizer) was historically dominant, generic competition has led to the vast majority of prescriptions being filled with generic Amlodipine Besylate.
• Manufacturing Capabilities: Competition is driven by cost-effective manufacturing, supply chain reliability, and securing contracts with large pharmacy benefit managers (PBMs) and healthcare systems.

Regulatory Environment and Patent Status

Amlodipine Besylate is off-patent globally. Generic manufacturers adhere to Food and Drug Administration (FDA) Abbreviated New Drug Application (ANDA) requirements for bioequivalence and quality.

• FDA Approval: Multiple ANDAs for Amlodipine Besylate 5mg tablets have been approved by the FDA, indicating a mature generic market.
• Post-Patent Market: The absence of patent protection allows for unrestricted generic entry, leading to price competition.

Market Size and Value

Estimating the precise market value for a specific NDC like 51672-2010 requires access to granular prescription data, which is proprietary. However, broad market trends for Amlodipine Besylate provide a proxy for understanding its economic significance.

Prescription Volume Trends

• High Prescription Volume: Amlodipine Besylate consistently ranks among the most prescribed medications in the United States and globally. Data from IQVIA and other market research firms routinely place it in the top tier for prescription volume.
• Volume Stability: While specific dosage forms and strengths may fluctuate, the overall demand for Amlodipine Besylate has remained relatively stable due to its essential nature in managing chronic conditions.

Pricing Dynamics

The price of generic Amlodipine Besylate 5mg tablets is subject to intense market forces.

• Average Wholesale Price (AWP): The AWP for generic Amlodipine Besylate 5mg tablets typically ranges from $0.10 to $0.50 per tablet, depending on the manufacturer, quantity purchased, and payer contracts. This is significantly lower than the branded equivalent's original price.
• Net Price Erosion: Actual net prices paid by payers are considerably lower due to rebates, discounts, and tiered formulary placements. These net prices are often confidential and negotiated directly between manufacturers and PBMs.
• Factors Influencing Price:
  • Number of Generic Manufacturers: A higher number of suppliers generally leads to lower prices.
  • Manufacturing Costs: Efficiency in active pharmaceutical ingredient (API) sourcing and tablet production is critical.
  • Payer Contracts: Agreements with large insurance providers and PBMs have a substantial impact on net pricing.
  • Wholesaler Markups: The wholesale distribution channel adds a layer of cost.

Price Projections

Predicting the precise price for NDC 51672-2010 involves forecasting the interplay of existing market dynamics and potential future shifts.

Current Pricing Environment

As of mid-2024, the market for Amlodipine Besylate 5mg tablets is characterized by:

• Intense Price Competition: The primary driver is the sheer number of generic manufacturers competing for market share.
• Negotiated Pricing: Prices are largely dictated by confidential contracts with payers, rather than list prices.
• Volume-Based Discounts: Larger purchasers and PBMs secure more favorable pricing.

Projected Price Trends

Based on current market conditions and historical performance of similar generic drugs, the following projections are made:

• Short-Term (1-2 years):

  • Price Stability with Slight Downward Pressure: Expect minimal significant price increases. The most probable scenario is continued price stability with gradual, incremental price erosion. This erosion will be driven by ongoing competition among manufacturers vying for PBM contracts and by the constant pursuit of cost efficiencies by payers. The average net price per tablet is unlikely to deviate by more than 5% from current levels.
  • No Major Disruptions: Without new significant patent challenges (which are irrelevant here) or major supply chain disruptions affecting multiple key players, dramatic price swings are improbable.

• Medium-Term (3-5 years):

  • Continued Erosion: The trend of price erosion is expected to continue, albeit at a potentially slower pace as the market matures and the lowest sustainable price points are approached by most manufacturers.
  • Impact of Payer Strategies: Changes in payer formulary strategies, such as preferred generic placements or value-based agreements, could exert further downward pressure.
  • Consolidation: Potential consolidation among smaller generic manufacturers could lead to some stabilization, but the overall competitive environment is likely to persist. The average net price could see a further decline of 5-10% over this period.

• Long-Term (5+ years):

  • Price Floor Realization: Prices will likely stabilize around the cost of production plus a minimal margin, as the market will have reached a point where further significant price reductions are not economically viable for most manufacturers.
  • Therapeutic Alternatives: The emergence of truly disruptive new therapeutic classes or technologies that significantly displace calcium channel blockers for hypertension or angina could impact demand and, consequently, pricing. However, given the chronic nature of these conditions and the established efficacy of amlodipine, such displacement is not anticipated in the near to medium term.

Factors Influencing Projections

• API Sourcing Costs: Fluctuations in the cost of active pharmaceutical ingredients, particularly those sourced from international markets, can impact manufacturing costs and, subsequently, pricing.
• Manufacturing Capacity and Supply Chain: Any disruption to global API supply chains or manufacturing capacity for key generic players could lead to temporary price volatility or shortages.
• Reimbursement Policies: Evolving Medicare and Medicaid reimbursement policies, as well as private payer formulary management, will continue to shape net pricing.
• Market Entry of New Competitors: While unlikely to be significant given the mature nature of the market, the entry of any new, highly efficient generic manufacturers could introduce additional competitive pressure.

Key Takeaways

• NDC 51672-2010, Amlodipine Besylate 5mg Tablets, operates in a mature, highly competitive generic drug market.
• Pricing is driven by manufacturing efficiency and PBM/payer contracts, not by novel patent-protected innovation.
• Short-to-medium term price projections indicate continued stability with moderate, gradual price erosion (5-10% over 3-5 years).
• Long-term pricing will likely stabilize around production costs.
• Key risks to projections include global supply chain disruptions and significant shifts in payer reimbursement strategies.

Frequently Asked Questions

1. What is the current average net price range for NDC 51672-2010 tablets? Precise net prices are confidential, but gross pricing suggests a range of $0.10 to $0.50 per tablet, with net prices significantly lower after rebates and discounts.

2. Are there any pending patent challenges that could affect the pricing of Amlodipine Besylate? Amlodipine Besylate is a well-established generic drug. All primary patents have long expired, and no significant new patent challenges are expected to impact the generic market.

3. What are the primary drivers of price erosion for this specific NDC? The primary drivers are intense competition among numerous generic manufacturers, economies of scale in production, and aggressive negotiation by pharmacy benefit managers and large healthcare systems.

4. How do manufacturing location and API sourcing influence the price of Amlodipine Besylate 5mg tablets? Manufacturers that can secure lower-cost API from reliable suppliers, particularly in regions with lower manufacturing overhead, can achieve a competitive pricing advantage.

5. Could the introduction of new dosage forms or combination therapies for hypertension significantly impact the market for Amlodipine Besylate 5mg tablets? While new therapies can influence the overall hypertension market, Amlodipine Besylate's established role as a first-line, cost-effective monotherapy for a broad patient population makes significant displacement by new entities unlikely in the short to medium term.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

[2] IQVIA. (Various Dates). Prescription Data Reports (Proprietary Market Intelligence).

[3] National Institutes of Health. (n.d.). Amlodipine Besylate. National Library of Medicine. Retrieved from https://medlineplus.gov/druginfo/meds/a691040.html

[4] American Heart Association. (n.d.). High Blood Pressure. Retrieved from https://www.heart.org/en/health-topics/high-blood-pressure

[5] European Medicines Agency. (n.d.). Amlodipine. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/amlodipine